December 2014 Archive
BaltSun: Five questions with Bill Niland, Harpoon Medical CEO
Friday, December 12, 2014
This Q&A originally appeared in The Baltimore Sun on December 12, 2014. Here is a brief excerpt. See link below for full story. Within a year and a half of launching as a startup, Harpoon Medical's heart surgery device could be used on humans for the first time in a matter of weeks. The Kent... read more
The BioBuzz on . . . Profectus BioSciences, Inc.’s President Jeffrey N. Meshulam
Thursday, December 11, 2014
Leader: Jeffrey “Jeff” Meshulam, President, Profectus BioSciences, Inc. Location: Baltimore, MD/Tarrytown, NY Overview: Profectus is a clinical-stage biotechnology company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines. Goal: To develop and... read more
PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial
Monday, December 8, 2014
PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously... read more
Grip Boost’s Spray Keeps Football Gloves Tacky, But They Need Manufacturing Help
Sunday, December 7, 2014
Tight end Matt Furstenburg had sticky hands as a three-year starter for the University of Maryland football team, good enough to later earn him a spot on the 2013 Baltimore Ravens practice squad. Furstenburg caught everything that came his way, but he noticed a problem with his football gloves.... read more